CERC News and Press, Cerecor Inc. From 01/07/21

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into a...

Gainers: [[OCC]] +40.5%. [[MRUS]] +27.2%. [[DRTT]] +22.2%. [[OEC]] +13.9%. [[WDFC]] +13.8%.Losers: [[SRPT]] -51.6%. [[SLDB]] -24.5%. [[BNGO]] -11.6%. [[UUU]] -9.7%. [[CERC]] -7.2%. For further details see: SRPT, BNGO, WDFC and MRUS among after-hours movers

Cerecor (CERC) shares traded 12% down after-hours after announcing its offer for sale shares to a certain investor in lieu thereof, pre-funded warrants to purchase shares of common stock, in an underwritten public offering; underwriters granted 30-day option to purchase up...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer f...

Cerecor ([[CERC]] +13.6%) announces results from its exploratory Phase 2 proof of concept trial of monoclonal antibody CERC-002 in patients hospitalized with COVID-19 associated pneumonia and mild-to-moderate acute respiratory distress syndrome.The trial included 83 patients who wer...

Aileron Therapeutics (ALRN) +73%.Broadway Financial Corporation (BYFC) +55% after regulatory approvals for merger with CFBanc Corporation.Atlantic American Corporation (AAME) +43%.Marker Therapeutics (MRKR) +30% after FDA lifted the partial clinical hold on it's Phase 2 trial.Cyclo ...

COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period) compared to placebo (n=62, odds ratio [OR]...

Cerecor ([[CERC]] +5.8%) announced that its Investigational New Drug Application to study the use of CERC-007 to treat Still’s disease has been accepted by the FDA and is now open.CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb).The first study will be...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Ap...

Cerecor (CERC) has dosed its first patient in a Phase 1b clinical trial of CERC-007, a fully human anti-IL-18 monoclonal antibody (mAb) being developed for patients with relapsed or refractory multiple myeloma ((MM)).The study will determine the recommended Phase 2 dose, safety and preliminar...